Uncategorized Archives - Page 28 of 87 - PsychedelicNewsWire (PNW)

ThursdayAug 05, 2021 1:15 pm

Massachusetts Legislators Consider Bill to Establish Task Force for Psychedelics

Last week, legislators in Massachusetts heard testimony about legislation that would establish a task force that would look into the consequences of legalizing psychedelic substances such as ayahuasca and psilocybin. The legislation was introduced by Rep. Mike Connolly, and while members of the Joint Judiciary Committee didn’t vote on the measure, Connolly made a case for the proposal, noting that emerging research proposed that entheogenic substances held significant therapeutic potential for various mental health conditions. He explained that serious issues, including addiction, anxiety, depression and post-traumatic stress disorder, were a challenge to address, which was why it was important to…

ThursdayAug 05, 2021 12:14 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Marks Milestone Moment as First Psychedelic Biotech to Trade on NYSE American Exchange

Company announces official approval for its common shares to be listed, traded on NYSE American Cybin will commit resources to reach the broadest investor audience, accelerate efforts to position Cybin as sector leader Companies that list on NYSE American can leverage a wide range of advantages In an historic move, Cybin (NEO: CYBN) (NYSE American: CYBN) will become the first psychedelic biotech company to trade on the NYSE American LLC stock exchange (https://ibn.fm/LQryy). Cybin received official approval for its common shares to be listed and traded on NYSE American last week, and the company anticipates that shares will start trading…

WednesdayAug 04, 2021 2:15 pm

More Adolescents Are Being Hospitalized During COVID-19 Due to Eating Disorders

A new study suggests that the number of teenagers who have been admitted to the hospital for serious illnesses caused by eating disorders has substantially grown during the coronavirus pandemic period. The research, which was published in the “Pediatrics” journal, found that in one hospital, admissions among adolescents who suffer from eating disorders had doubled during the first year of the COVID-19 pandemic. The center, Michigan Medicine, stated that while admissions linked to eating disorders in the years 2017 to 2019 averaged about 55 individuals annually, the center had recorded more than 120 hospitalizations in the pandemic’s first year, with…

TuesdayAug 03, 2021 1:45 pm

General Public’s Perception on Dangers of Psilocybin Mushrooms Align with Science

A new study suggests that the general public’s perception of the possible harms of psilocybin mushrooms doesn’t align with drug laws. The study found that magic mushrooms were considered to be less dangerous in comparison with tobacco, alcohol and other substances. The study was published in the “Journal of Psychopharmacology.” The study’s author, professor Carl Roberts from the department of psychology at the University of Liverpool, stated that he was greatly interested in how substances affected an individual’s behavior as well as their brain. He explained that he had been following research on the therapeutic potential of psychedelic substances such…

MondayAug 02, 2021 2:45 pm

Study Finds That LSD Affects Language Production in the Brain

A recent study published in the “Consciousness and Cognition” journal has found that language produced while an individual is under the influence of LSD shows decreased semantic coherence and increased entropy levels. In layman’s terms, this means that people were more likely to move from one topic to another and have more disorganized speech while under the influence of LSD. Entropy was developed by physicists to quantify lost energy in mechanical systems. However, researchers have found that this measure of randomness and uncertainty in a system can also be used to measure spontaneous activity in brain networks. Study author Enzo…

FridayJul 30, 2021 2:40 pm

Ketamine Treatment Study Conducted During Pandemic Highlights Antidepressant Properties

The coronavirus pandemic has affected many industries and economies around the world, in addition to affecting global physical health, with continuous disconnection and social isolation aggravating the mental health crisis further. It has also emphasized the need to find new ways to improve the treatment of mental health conditions, with one recent study reporting that ketamine held the potential to become an effective treatment for depression when administered during the pandemic. Ketamine is mainly used as an anesthetic but has also demonstrated that it can be used to treat depression. The study, which was reported in the “Psychiatry Research” journal,…

ThursdayJul 29, 2021 2:53 pm

Congresswoman Introduces Amendment to Remove Barriers Impeding Psychedelic Research

Rep. Alexandria Ocasio-Cortez recently introduced an amendment in Congress that would remove a federal research barrier on psychedelics and, in turn, promote studies on the therapeutic potential of psychedelics such as ibogaine, psilocybin and MDMA. The congresswoman’s measure would be opposing an amendment that was first enacted in the late 1990s, which prohibits federal funds from being used in any activity that promotes the legalization of substances or drugs classified under Schedule I of the Controlled Substances Act. The measure also includes a provision that directs the FDA to establish a regulatory pathway allowing CBD to also be dispensed as…

WednesdayJul 28, 2021 1:30 pm

Psilocybin Causes Sustained Neural Connection Growth, Study Finds

Researchers from Yale University have discovered that one dose of psilocybin administered to mice causes a quick and lasting increase in connections between neurons in the area of the brain involved in cognitive processes, known as the medial frontal cortex. Their discovery was reported in the “Neuron” journal. Prior research has found that psilocybin, which is the active compound found in psilocybin mushrooms, has long-lasting and profound effects on mood and personality, with some preliminary studies providing evidence that the compound could be used to alleviate symptoms of mental health conditions such as depression. However, the mechanisms underlying these effects…

WednesdayJul 28, 2021 9:00 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent, Adds New Dimension to Development Strategy

Digital therapeutics platform is proprietary to Cybin and the subject of the company’s 13th patent application Company focused on utilizing, leveraging cutting-edge technologies to support drug-development candidates Cybin is confident this added focus will better enable the evaluation of patient outcomes Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company, has taken another step forward in its strategic focus on progressing psychedelic therapeutics, with the filing of its 13th provisional patent application (https://ibn.fm/xTawm). In addition to the patent filing, the company has also advanced the build-out of its digital therapeutics strategy. “The digital therapeutics platform, which is proprietary to Cybin and the…

TuesdayJul 27, 2021 3:00 pm

New Zealand to Conduct LSD Micro-Dosing Trial Targeting Cancer Patients

Researchers in New Zealand plan to run an LSD micro-dosing trial with patients in the advanced stages of cancer in an attempt to see whether the drug will improve their quality of life. The trial will be led by University of Auckland’s director of the postgraduate diploma in health psychology, Dr. Lisa Reynolds. In an interview with a popular radio station, Reynolds stated that thus far, research had shown that psychedelic substances such as LSD possessed the potential to increase spirituality, decrease depression and anxiety, decrease the fear of death, and improve an individual’s quality of life. The objective of…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized